Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Breaking Down the Data in Genitourinary, Gastrointestinal, and Breast Cancers, Plus Sarcoma and Melanoma at ASCO 2023: Drs Rini, Lewis, Trent, Luke, Kunz, and Lustberg

June 6th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

Dr Tawbi on Nivolumab Plus Relatlimab in Metastatic Melanoma

June 5th 2023

Hussein A. Tawbi, MD, PhD, discusses the 2-year findings from the phase 2/3 RELATIVITY-047 trial of nivolumab plus relatlimab in treatment-naïve patients with metastatic or unresectable melanoma.

PRT811 Elicits Responses and Shows Safety in Advanced Glioma and Uveal Melanoma

June 5th 2023

The protein arginine methyltransferase 5 brain-penetrant inhibitor PRT811 demonstrated preliminary antitumor activity and acceptable safety for patients with recurrent high-grade glioma and advanced or metastatic uveal melanoma, according to data from the dose-expansion portion of a phase 1 trial presented at the 2023 ASCO Annual Meeting.

FDA Grants Priority Review to Lifileucel in Advanced Melanoma

May 30th 2023

The FDA has granted priority review to the biologics license application for the tumor infiltrating lymphocyte therapy lifileucel for the treatment of patients with advanced melanoma who progressed on or after prior anti–PD-1/PD-L1 therapy and targeted therapy.

Closing Thoughts on Intralesional Therapy for Melanoma and CSCC

May 24th 2023

A panel of skin cancer experts offer closing thoughts on intralesional therapy for treating melanoma and CSCC.

Optimizing CSCC Management Requires a Multifaceted Approach to Care

May 17th 2023

Sunandana Chandra, MD, MS, Anna C. Pavlick, DO, MSc, MBA, BSN, and Nikhil Khushalani, MD, discuss the importance of multidisciplinary care in CSCC and patient counseling regarding available therapies.

Tumor-Directed Oncolytic Therapies for Melanoma and CSCC

May 17th 2023

An expert panel discusses the use of tumor-directed oncolytic therapies for melanoma and cutaneous squamous cell carcinoma.

Treating Patients with High-Risk Melanoma

May 17th 2023

A comprehensive overview of treatment approaches for patients with high-risk melanoma.

Meaningful End Points for Patients with Metastatic Melanoma

May 10th 2023

Experts on skin cancer discuss valuable end points for determining successful treatments for patients with metastatic melanoma.

Deciding Between Melanoma Therapy Options

May 10th 2023

A panel of skin cancer experts share their thoughts on treatment selection for patients with melanoma.

IRAK-4 Inhibitor CA-4948 May Enhance Immunotherapeutic Outcomes in Melanoma With Brain Metastases

May 5th 2023

Bently Doonan, MD, discusses how CA-4948 can penetrate the blood-brain barrier and interact with the tumor microenvironment, and how this approach may open doors for patients with melanoma who have brain metastases.

Early ctDNA Testing Provides Another Tool for Predicting Survival Outcomes With Tebentafusp in Metastatic Uveal Melanoma

May 4th 2023

Ryan J. Sullivan, MD, discusses previous research on tebentafusp in uveal melanoma that led to the inception of the IMCgp100-202 trial and clinical implications for data confirming the predictive value of circulating tumor DNA levels.

Dr Sriramareddy on the Relationship Between Uveal Melanoma and the Liver Metastases

May 3rd 2023

Sathya Neelature Sriramareddy, MD, PhD, discusses how the interaction between uveal melanoma cells and the liver microenvironment could influence metastasis growth and therapeutic response.

Practical Advice on the Evolving Management of CSCC

May 3rd 2023

Closing out their discussion on the management of cutaneous squamous cell carcinoma, expert panelists share clinical pearls and excitement for the future.

BRAF/MEK Dual Inhibitors for Melanoma

May 3rd 2023

An expert panel analyzes BRAF/MEK dual inhibitor therapy for the treatment of melanoma.

Factors that Impact Treatment Selection for Melanoma

May 3rd 2023

Anna C. Pavlick, DO, discusses factors that impact treatment selection for patients with melanoma.

FDA Grants Regular Approval to Cemiplimab for Metastatic Basal Cell Carcinoma

May 1st 2023

The FDA has granted full approval to cemiplimab-rwlc for the treatment of patients with metastatic basal cell carcinoma who previously received a hedgehog inhibitor (HHI) or for whom a HHI is not appropriate.

A Phase 1 Clinical Trial Evaluating Monotherapy With Exarafenib (KIN-2787), a Highly Selective Pan-RAF Inhibitor, in BRAF‑Altered Solid Tumors and NRAS-Mutant Melanoma

April 27th 2023

Alexander I. Spira, MD, PhD, shares new dose escalation data from the first-in-human Phase 1 KIN-2787 study of the pan-RAF inhibitor exarafenib in patients with BRAF-altered solid tumors or NRAS-mutant melanoma.

CSCC: Escalating Therapy for High-risk Patients

April 26th 2023

Dr Vishal Patel shares a surgeon’s perspective on MDC, followed by a discussion on how intensifying treatment after surgery may improve outcomes for higher-risk patients with CSCC.

Best Practices in Multidisciplinary Care for CSCC

April 26th 2023

Experts in the field of CSCC revisit the concept of multidisciplinary care and consider best communication strategies.